1. Alvarez-Erviti L, Seow Y, Yin H, Betts C, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011;29:341–5.
2. Aronin N, DiFiglia M. Huntingtin-lowering strategies in Huntingtonʼs disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 2014;29:1455–61.
3. Aubry L, Bugi A, Lefort N, Rousseau F, et al. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci U S A 2008;105:16707–12.
4. Bachoud-Levi A, Bourdet C, Brugieres P, Nguyen JP, et al. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntingtonʼs disease. Exp Neurol 2000;161:194–202.
5. Bachoud-Levi AC, Gaura V, Brugieres P, Lefaucheur JP, et al. Effect of fetal neural transplants in patients with Huntingtonʼs disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5:303–9.
6. Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, et al. Motor and cognitive improvements in patients with Huntingtonʼs disease after neural transplantation. Lancet 2000;356:1975–9.
7. Barker RA, Mason SL, Harrower TP, Swain RA, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntingtonʼs disease. J Neurol Neurosurg Psychiatry 2013;84:657–65.
8. Carroll JB, Warby SC, Southwell AL, Doty CN, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 2011;19:2178–85.
9. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntingtonʼs disease. Nat Rev Neurosci 2005;6:919–30.
10. Cicchetti F, Lacroix S, Cisbani G, Vallieres N, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 2014;76:31–42.
11. Delli Carri A, Onorati M, Lelos MJ, Castiglioni V, et al. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development 2013;140:301–12.
12. DiFiglia M, Sapp E, Chase KO, Davies SW, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990–3.
13. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A 2007;104:17204–9.
14. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000;26:300–6.
15. Gagnon KT, Pendergraff HM, Deleavey GF, Swayze EE, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 2010;49:10166–78.
16. Godin JD, Colombo K, Molina-Calavita M, Keryer G, et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010;67:392–406.
17. Grondin R, Kaytor MD, Ai Y, Nelson PT, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 2012;135(Pt 4):1197–209.
18. Harper SQ, Staber PD, He X, Eliason SL, et al. RNA interference improves motor and neuropathological abnormalities in a Huntingtonʼs disease mouse model. Proc Natl Acad Sci U S A 2005;102:5820–5.
19. Hu J, Liu J, Corey DR. Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 2010;17:1183–8.
20. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366–72.
21. Hurelbrink CB, Armstrong RJ, Dunnett SB, Rosser AE, et al. Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci 2002;15:1255–66.
22. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, et al. Sustained therapeutic reversal of Huntingtonʼs disease by transient repression of huntingtin synthesis. Neuron 2012;74:1031–44.
23. Li H, Haurigot V, Doyon Y, Li T, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011;475:217–21.
24. Lima WF, Prakash TP, Murray HM, Kinberger GA, et al. Single-stranded siRNAs activate RNAi in animals. Cell 2012;150:883–94.
25. Lopez WO, Nikkhah G, Schultke E, Furlanetti L, et al. Stereotactic planning software for human neurotransplantation: suitability in 22 surgical cases of Huntingtonʼs disease. Restor Neurol Neurosci 2014;32:259–68.
26. McBride JL, Pitzer MR, Boudreau RL, Dufour B, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntingtonʼs disease. Mol Ther 2011;19:2152–62.
27. Miller TM, Pestronk A, David W, Rothstein J, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013;12:435–42.
28. Nasir J, Floresco SB, OʼKusky JR, Diewert VM, et al. Targeted disruption of the Huntingtonʼs disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811–23.
29. Niewoehner J, Bohrmann B, Collin L, Urich E, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014;81:49–60.
30. Olson SD, Kambal A, Pollock K, Mitchell GM, et al. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntingtonʼs disease affected neuronal cells for reduction of huntingtin. Mol Cell Neurosci 2012;49:271–81.
31. Olson SD, Pollock K, Kambal A, Cary W, et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntingtonʼs disease. Mol Neurobiol 2012;45:87–98.
32. Paganini M, Biggeri A, Romoli AM, Mechi C, et al. Fetal striatal grafting slows motor and cognitive decline of Huntingtonʼs disease. J Neurol Neurosurg Psychiatry 2014;85: 974–81.
33. Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC. The cognitive burden in Huntingtonʼs disease: pathology, phenotype, and mechanisms of compensation. Mov Disord 2014;29:673–83.
34. Papworth M, Kolasinska P, Minczuk M. Designer zinc-finger proteins and their applications. Gene 2006;366:27–38.
35. Paradisi I, Hernandez A, Arias S. Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation. J Hum Genet 2008;53:127–35.
36. Pfister EL, Kennington L, Straubhaar J, Wagh S, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntingtonʼs disease patients. Curr Biol 2009;19:774–8.
37. Precious SV, Rosser AE. Producing striatal phenotypes for transplantation in Huntingtonʼs disease. Exp Biol Med 2012; 237:343–51.
38. Pringsheim T, Wiltshire K, Day L, Dykeman J, et al. The incidence and prevalence of Huntingtonʼs disease: a systematic review and meta-analysis. Mov Disord 2012;27:1083–91.
39. Stanek LM, Sardi SP, Mastis B, Richards AR, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntingtonʼs disease. Hum Gen Ther 2014;25:461–74.
40. Stiles DK, Zhang Z, Ge P, Nelson B, et l. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 2012;233:463–71.
41. Tabrizi SJ, Scahill RI, Owen G, Durr A, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntingtonʼs disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637–49.
42. The Huntingtonʼs Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtonʼs disease chromosomes. Cell 1993;72:971–83.
43. van Duijn E, Craufurd D, Hubers AA, Giltay EJ, et al. Neuropsychiatric symptoms in a European Huntingtonʼs disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 2014;85:1411–8.
44. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, et al. Neuropathological classification of Huntingtonʼs disease. J Neuropathol Exp Neurol 1985;44:559–77.
45. Wang N, Gray M, Lu XH, Cantle JP, et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntingtonʼs disease. Nat Med 2014;20:536–41.
46. Warby SC, Visscher H, Collins JA, Doty CN, et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 2011;19:561–6.
47. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntingtonʼs disease. Cell 2000;101:57–66.
48. Yu D, Pendergraff H, Liu J, Kordasiewicz HB, et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012;150:895–908.
Dr. Zacharias Kohl, Universitätsklinikum Erlangen, Molekulare Neurologie, Schwabachanlage 6, 91054 Erlangen, E-Mail: email@example.com